In ovarian cancer, preclinical studies demonstrate that gold NPs suppress cisplatin-induced EMT and stemness in A2780 and SKOV3 models, reducing MDR1/ABCG2 expression and sensitising tumours to platinum chemotherapy [217]. This evidence concerns the gene ABCB1 and ovarian cancer.